# Abcuro funding rounds and investors

As of 14 Oct 2026, Abcuro has raised $200M across 1 verified round on record; latest: $200 million Series C led by New Enterprise Associates, announced 12 Feb 2025.

Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions.

Website: https://abcuro.com  
Headquarters: Newton, Massachusetts  
Page: https://fireround.dev/companies/abcuro.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-02-12 | Series C | $200 million | New Enterprise Associates | abrdn, Bain Capital Life Sciences, BlackRock, Eurofarma Ventures, Foresite Capital, Mass General Brigham Ventures, New Leaf Ventures, Pontifax, RA Capital Management, Redmile Group, Samsara BioCapital, Sanofi Ventures, Soleus Capital | [abcuro.com](https://abcuro.com/uncategorized/abcuro-announces-200-million-series-c-financing-to-advance-its-first-in-class-medicine-in-development-for-inclusion-body-myositis), [biospace.com](https://www.biospace.com/press-releases/abcuro-announces-200-million-series-c-financing-to-advance-its-first-in-class-medicine-in-development-for-inclusion-body-myositis) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.